Company Overview

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on the development of RNA medicines and vaccines using messenger RNA (mRNA) technologies. The company operates primarily in the biotechnology and pharmaceutical industries, with a concentration on infectious diseases, rare diseases, and chronic conditions that may benefit from nucleic acid-based therapeutics. Arcturus is known for its proprietary lipid-mediated delivery and self-amplifying mRNA technology platforms, which are intended to improve the durability and efficiency of RNA expression. The company generates value primarily through research and development collaborations, licensing arrangements, government-supported vaccine programs, and advancement of proprietary therapeutic candidates.

The company’s core technology platforms include LUNAR® lipid nanoparticle delivery technology and self-amplifying mRNA platforms designed for lower-dose therapeutic and vaccine applications. Arcturus has pursued strategic positioning through partnerships with government agencies and pharmaceutical organizations, particularly in vaccine development and pandemic preparedness initiatives. Founded in 2013 and headquartered in San Diego, California, the company evolved from an early-stage RNA therapeutics developer into a broader clinical-stage biotechnology company with programs spanning respiratory vaccines and rare genetic diseases.

Business Operations

Arcturus conducts operations primarily through integrated biotechnology research and clinical development activities centered around RNA therapeutics and vaccines. Its business activities include discovery research, preclinical development, clinical trials, manufacturing process development, and commercialization partnerships. The company’s major operational focus areas include infectious disease vaccines, cystic fibrosis therapies, ornithine transcarbamylase deficiency programs, and other RNA-based therapeutic candidates. Revenue has historically been derived from collaborative agreements, milestone payments, licensing arrangements, and government-supported development contracts rather than large-scale commercial product sales.

Internationally, Arcturus has expanded its operational reach through strategic collaborations, particularly in Asia and global vaccine markets. The company has maintained partnerships involving manufacturing, regional commercialization, and development support. Notable collaborations have included relationships with CSL Seqirus and entities involved in regional vaccine commercialization and development efforts. Arcturus controls proprietary intellectual property associated with RNA chemistry, delivery systems, and manufacturing processes that form the basis of its competitive positioning in the RNA therapeutics sector.

Strategic Position & Investments

Arcturus has focused its strategic direction on advancing self-amplifying mRNA therapeutics and vaccines, emphasizing differentiated delivery technologies and lower-dose RNA approaches. The company has invested heavily in clinical-stage vaccine programs, including COVID-19-related candidates and broader infectious disease pipelines. Management has consistently communicated a strategy centered on platform scalability, strategic partnerships, and expansion into additional therapeutic categories where RNA delivery remains a technical barrier for competitors.

The company’s investment priorities include expanding manufacturing capabilities, advancing rare disease programs, and strengthening intellectual property protections around RNA delivery systems. Arcturus has also pursued collaborations designed to support commercialization outside the United States and to diversify development funding sources. Its involvement in emerging RNA medicine technologies positions the company within a competitive field that includes larger pharmaceutical and biotechnology firms pursuing mRNA therapeutics, although Arcturus differentiates itself through self-amplifying RNA development and proprietary delivery technologies. Data regarding long-term commercial market share potential remains inconclusive based on available public sources.

Geographic Footprint

Arcturus Therapeutics is headquartered in San Diego, California, and operates primarily within the United States, while maintaining strategic partnerships and commercial relationships internationally. The company’s clinical development, regulatory activities, and manufacturing collaborations extend into parts of Asia, Europe, and other global healthcare markets through partnership-based structures rather than large standalone foreign operating divisions.

The company’s international presence has been particularly visible in vaccine-related collaborations and regional commercialization arrangements. Arcturus has participated in cross-border development initiatives involving manufacturing and distribution support in international markets. While its direct employee footprint remains concentrated in the United States, its operational influence extends globally through licensing agreements, clinical trial activity, and strategic development partnerships.

Leadership & Governance

Arcturus Therapeutics was co-founded by scientists and biotechnology executives focused on advancing RNA-based medicines and delivery technologies. The company operates under a governance structure typical of publicly traded biotechnology firms, with executive leadership overseeing clinical development, regulatory strategy, manufacturing, and corporate finance. Leadership communications have emphasized long-term investment in platform technologies, disciplined clinical execution, and strategic partnerships to accelerate commercialization opportunities.

Key executives and leadership figures include:

• Joseph E. Payne – President and Chief Executive Officer
• Pad Chivukula, Ph.D. – Chief Scientific Officer
• Charles H. Theuer, M.D., Ph.D. – Chief Medical Officer
• David Meek – Chief Financial Officer
• Nicolas Guzman, Ph.D. – Senior scientific leadership roles associated with platform and technology development

The company’s governance and operational disclosures have been presented through public filings including SEC filings, earnings materials, and investor communications. Certain executive role changes and organizational updates may vary over time based on company disclosures and reporting periods.